Information Provided By:
Fly News Breaks for September 15, 2015
MYGN
Sep 15, 2015 | 05:41 EDT
Mizuho analyst Eric Criscuolo raised his price target for Myriad Genetics to $38 citing improved visibility into reimbursement and strategy following the company's analyst day. Myriad's new long-term outlook of 2015-2020 CAGR of 10% is above consensus and looks achievable, but "several moving parts need to work," Criscuolo tells investors in a research note. He keeps a Neutral rating on the stock.
News For MYGN From the Last 2 Days
MYGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.